Literature DB >> 22726083

How I treat inhibitors in haemophilia.

M Makris1, C R M Hay, A Gringeri, R D'Oiron.   

Abstract

The management of patients with inhibitors is the greatest challenge facing haemophilia health professionals. Immune tolerance induction (ITI) can be successful in eliminating the inhibitor in the majority of patients, provided it is started soon after the inhibitor develops and the titre of the inhibitor is <10 BU at commencement of ITI. Acute bleeding is treated using one of two bypassing agents, which exhibit similar efficacy and safety. Surgery in inhibitor patients is challenging and should only be carried out in experienced centres.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22726083     DOI: 10.1111/j.1365-2516.2012.02829.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Skin testing, graded challenge, and desensitization to von Willebrand factor (VWF) products in type III von Willebrand disease (VWD).

Authors:  Craig D Platt; Loren D'Angelo; Ellis J Neufeld; Ana Dioun Broyles
Journal:  J Allergy Clin Immunol Pract       Date:  2016-07-09

Review 2.  Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.

Authors:  C H Miller
Journal:  Haemophilia       Date:  2018-02-15       Impact factor: 4.287

3.  Successful Desensitization of a Patient with Possible IgE-Mediated Anaphylactic Reaction to FVIII/VWF Concentrate.

Authors:  Burcin Beken; Velat Celik; Pinar Gokmirza Ozdemir; Tuba Eren; Mehtap Yazicioglu
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-06-17       Impact factor: 1.349

Review 4.  Current animal models of hemophilia: the state of the art.

Authors:  Ching-Tzu Yen; Meng-Ni Fan; Yung-Li Yang; Sheng-Chieh Chou; I-Shing Yu; Shu-Wha Lin
Journal:  Thromb J       Date:  2016-10-04

Review 5.  Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX.

Authors:  Angiola Rocino; Massimo Franchini; Antonio Coppola
Journal:  J Clin Med       Date:  2017-04-17       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.